Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follitropin alfa/lutropin alfa

Next Previous
X
Search
Drug Profile

Follitropin alfa/lutropin alfa

Alternative Names: Lutropin alfa/follitropin alfa; Pergoveris; Recombinant human follicle stimulating hormone/luteinising hormone; rh-FSH/LH

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serono Europe
  • Developer Merck KGaA; Merck Serono Co Ltd; Serono Europe
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Luteinising hormone stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Female-infertility in China (SC, Injection)
  • 28 May 2022 Merck KGaA completes a phase-I trial in Female infertility in China (SC) (NCT04899193)
  • 08 May 2021 Phase-I clinical trials in Female infertility in China (SC) (NCT04899193)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top